ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Polymeric prosthetic heart valves with low thrombogenicity

S. Melo1, A. Aqil2, B. Ditkowski3, C. Jérôme2, P. Lancellotti4, C. Oury3

1University of Liège - GIGA , Liège, Liege, Belgium, 2Center for Education and Research on Macromolecules (CERM), CESAM-UR, University of Liège, B-4000 Liège, Belgium, Liège, Liege, Belgium, 3Laboratory of Cardiology, GIGA-Cardiovascular Sciences, University of Liège, Liège, Belgium, Liège, Liege, Belgium, 4Laboratory of Cardiology, GIGA Institute, University of Liège, Liège, Belgium; Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola, and Anthea Hospital, Bari, Italy, Liege, Liege, Belgium

Abstract Number: PB0422

Meeting: ISTH 2022 Congress

Theme: Venous Thromboembolism » Artificial Valves

Background: Valvular heart diseases (VHD) affect about 13% of the elder population (>75), which represents more than 100 million people worldwide. The only available treatment is heart valve replacement, either with mechanical or biological prostheses. Mechanical prostheses provide long-term durability, but inevitably bring along a high risk of thromboembolism. On the other hand, biological prostheses provide better hemo/biocompatibility, but they are prone to degeneration. Alternatively, polymeric (particularly polyurethane(PU)-derived) materials have been suggested and investigated as potential heart valve biomaterials.

Aims: To develop and test innovative non-isocyanate polyhydroxyurethanes (PHUs) for prosthetic heart valves, with improved mechanical and anti-thrombogenic properties, resulting in enhanced hemocompatibility.

Methods: PHUs were obtained by polyaddition between different bis-cyclic-carbonates and amines. The ultimate tensile strength (MPa), strain (%) and elastic modulus (MPa) of synthesized PHUs were measured under dry and wet conditions and compared to native valves. Hemolysis tests were performed in the presence of washed red blood cells from human blood. The activation of the complement and coagulation cascade was evaluated after incubation of the PHU samples with citrate-anticoagulated platelet-poor plasma. Platelet adhesion was quantified upon incubation of the samples with platelet-rich plasma.

Results: A Dacron reinforcement of the selected PHU rendered mechanical properties that were comparable to the ones of a native valve. This PHU did not cause hemolysis or complement activation, it induced less coagulation activation than medical grade PU, and caused extremely low levels of platelet adhesion. A tri-leaflet prosthetic heart valve with a precisely defined design was produced by injection molding.

Conclusion(s): PHU materials displayed overall improved hemocompatibility. A cost effective, environmentally friendly and mechanically competent prosthetic heart valve was developed and could be further explored as an alternative for valve replacement in VHD patients.

To cite this abstract in AMA style:

Melo S, Aqil A, Ditkowski B, Jérôme C, Lancellotti P, Oury C. Polymeric prosthetic heart valves with low thrombogenicity [abstract]. https://abstracts.isth.org/abstract/polymeric-prosthetic-heart-valves-with-low-thrombogenicity/. Accessed October 1, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/polymeric-prosthetic-heart-valves-with-low-thrombogenicity/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley